NGN Capital targets biotech

Newcomer NGN Capital has unveiled its debut fund, NGN BioMed I. The fund will invest in the healthcare and biotech space including drug products, medical devices and the services sector. Investments will be diversified by stage, from later stage to selected early stage opportunities, as well as by geography and will invest predominantly in the US and Europe.

The fund has raised around $96m so far. Half this was committed by German pharmaceuticals company, Boehringer. So far, the rest of the investors in the fund have come from the US.

NGN Capital is comprised of a professional team and advisors, with investment and management backgrounds in the healthcare and venture capital industry worldwide.

NGN Capital has offices in the US in New York and its European office is in Heidelberg, Germany.